Suppr超能文献

Words of Wisdom. Re: Nivolumab Versus Everolimus in Advanced Renal-Cell Carcinoma.

作者信息

Mulders Peter F A

机构信息

Department of Urology, Radboud University Medical Centre Nijmegen, The Netherlands.

出版信息

Eur Urol. 2016 Apr;69(4):753-4. doi: 10.1016/j.eururo.2016.01.018. Epub 2016 Feb 18.

Abstract
摘要

相似文献

1
Words of Wisdom. Re: Nivolumab Versus Everolimus in Advanced Renal-Cell Carcinoma.
Eur Urol. 2016 Apr;69(4):753-4. doi: 10.1016/j.eururo.2016.01.018. Epub 2016 Feb 18.
2
CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival.
Nat Rev Urol. 2015 Dec;12(12):651. doi: 10.1038/nrurol.2015.246. Epub 2015 Oct 13.
3
Kidney cancer: CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival.
Nat Rev Clin Oncol. 2015 Nov;12(11):621. doi: 10.1038/nrclinonc.2015.178. Epub 2015 Oct 13.
4
Words of Wisdom. Re: Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Eur Urol. 2016 Mar;69(3):538-9. doi: 10.1016/j.eururo.2015.12.025.
5
Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple Kinases.
N Engl J Med. 2015 Nov 5;373(19):1872-4. doi: 10.1056/NEJMe1511252. Epub 2015 Sep 25.
6
Cabozantinib and nivolumab for renal cell carcinoma.
Lancet Oncol. 2015 Nov;16(15):e531. doi: 10.1016/S1470-2045(15)00377-0. Epub 2015 Oct 5.
8
Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy.
Eur Urol. 2016 Jan;69(1):4-6. doi: 10.1016/j.eururo.2015.10.017. Epub 2015 Oct 24.
10
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
N Engl J Med. 2015 Nov 5;373(19):1814-23. doi: 10.1056/NEJMoa1510016. Epub 2015 Sep 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验